Format

Send to

Choose Destination
See comment in PubMed Commons below
Nanomedicine. 2016 Nov 25;13(3):965-976. doi: 10.1016/j.nano.2016.11.010. [Epub ahead of print]

Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.

Author information

1
Irell & Manella Graduate School of Biological Sciences, City of Hope-Beckman Research Institute, Duarte, California, USA; Department of Stem Cell and Developmental Biology, City of Hope-Beckman Research Institute Duarte, California, USA. Electronic address: cai.roberts@yale.edu.
2
Irell & Manella Graduate School of Biological Sciences, City of Hope-Beckman Research Institute, Duarte, California, USA; Department of Stem Cell and Developmental Biology, City of Hope-Beckman Research Institute Duarte, California, USA. Electronic address: sshahin@coh.org.
3
Department of Chemistry and Biochemistry, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, University of California Los Angeles, Los Angeles, California, USA. Electronic address: wwen@coh.org.
4
Irell & Manella Graduate School of Biological Sciences, City of Hope-Beckman Research Institute, Duarte, California, USA; Department of Stem Cell and Developmental Biology, City of Hope-Beckman Research Institute Duarte, California, USA. Electronic address: jamesfinlay@gmail.com.
5
Department of Chemistry and Biochemistry, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, University of California Los Angeles, Los Angeles, California, USA. Electronic address: juyao@mit.edu.
6
Department of Chemistry and Biochemistry, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, University of California Los Angeles, Los Angeles, California, USA. Electronic address: wangrn8600@gmail.com.
7
Department of Surgery, City of Hope-Beckman Research Institute, California, USA. Electronic address: tdellinger@coh.org.
8
Department of Chemistry and Biochemistry, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, University of California Los Angeles, Los Angeles, California, USA. Electronic address: zink@chem.ucla.edu.
9
Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, University of California Los Angeles, Los Angeles, California, USA. Electronic address: fuyut@microbio.ucla.edu.
10
Department of Stem Cell and Developmental Biology, City of Hope-Beckman Research Institute Duarte, California, USA. Electronic address: cglackin@coh.org.

Abstract

Epithelial ovarian cancer (EOC) is the most deadly gynecologic malignancy on account of its late stage at diagnosis and frequency of drug resistant recurrences. Novel therapies to overcome these barriers are urgently needed. TWIST is a developmental transcription factor reactivated in cancers and linked to angiogenesis, metastasis, cancer stem cell phenotype, and drug resistance, making it a promising therapeutic target. In this work, we demonstrate the efficacy of TWIST siRNA (siTWIST) and two nanoparticle delivery platforms to reverse chemoresistance in EOC models. Polyamidoamine dendrimers and mesoporous silica nanoparticles (MSNs) carried siTWIST into target cells and led to sustained TWIST knockdown in vitro. Mice treated with cisplatin plus MSN-siTWIST exhibited lower tumor burden than mice treated with cisplatin alone, with most of the effect coming from reduction in disseminated tumors. This platform has potential application for overcoming the clinical challenges of metastasis and chemoresistance in EOC and other TWIST overexpressing cancers.

KEYWORDS:

Mesoporous silica nanoparticles; Ovarian cancer; Polyamidoamine dendrimers; Twist; siRNA

PMID:
27890656
DOI:
10.1016/j.nano.2016.11.010
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center